Higher Risk of Blood Clots With Some Birth Control Pills


Birth control pills that contain drospirenone may be associated with a higher risk of blood clots than other progestin-containing pills. FDA bases this conclusion on its review of recent studies on the risk of blood clots in women taking drospirenone-containing birth control pills.

Drospirenone is a synthetic version of the female hormone progesterone, also referred to as a progestin. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills, which include:

  • Beyaz
  • Drospirenone and ethinyl estradiol
  • Gianvi
  • Loryna
  • Ocella
  • Safyral
  • Syeda
  • Yasmin
  • Yaz
  • Zarah

Risk: The revised drug labels will state that some studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing levonorgestrel or some other progestins, but other studies found no additional risk of blood clots with drospirenone-containing products.

Recommendation: Women should talk to their health care professional about their risk for blood clots before deciding which birth control method to use.

For More Information

FDA Drug Safety Communication on the Risk of Blood Clots in Women Taking Birth Control Pills Containing Drospirenone

Created on May 16, 2012